Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
NCT ID: NCT00693004
Last Updated: 2009-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
236 participants
INTERVENTIONAL
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
PRX-03140
PRX-03140
donepezil
Donepezil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRX-03140
Donepezil
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MMSE score 16 to 24 inclusive
* Age \>50 and \<90 years
* Brain CT or MRI scan Consistent with a primary diagnosis of AD within 12 months
* Neurological examination without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)
* No history or evidence of any other CNS disorder that could be interpreted as a cause of dementia
* No diagnosis of vascular dementia
* No history of significant psychiatric illness such as schizophrenia or bipolar affective disorder. Subjects with major depressive disorder on a stable dose of an antidepressant for \>6 months may be eligible
* No evidence of the following: current vitamin B12 deficiency, positive syphilis serology, positive HIV test, or abnormalities in thyroid function
* No cognitive rehabilitation within 6 months of the study
* Subject has a regular caregiver willing to attend all study visits
* Signed informed consent by the subject (and legal guardian, if applicable)
Exclusion Criteria
* No clinically significant laboratory abnormalities or medical history
* No investigational drug within 30 days of Randomization
* Intolerance or allergy to cholinesterase inhibitors
* Cannot have been on cholinesterase inhibitors for AD for \> 2 years
* If have been on cholinesterase inhibitors for \< 2 years, must have been discontinued \>= 2 months prior to randomization
* Cannot have received memantine within 2 months
* No clinically significant ECG abnormalities prior to randomization
* No history of uncontrolled seizure disorder within 12 months
* Cannot be taking MAO inhibitors, bupropion,fluoxetine, paroxetine, quinidine
* No history of malignancy within 3 years of randomization
* Women cannot be pregnant or breastfeeding
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Epix Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
EPIX Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barrow Neurological Institute
Phoenix, Arizona, United States
PsyPharma Clinical Research, Inc.
Phoenix, Arizona, United States
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Synergy Clinical Research Center
National City, California, United States
Pacific Neuroscience Medical Group
Oxnard, California, United States
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California, United States
Torrance Clinical Research
Torrance, California, United States
Bradenton Research Center
Bradenton, Florida, United States
Brain Matters Research
Delray Beach, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Compass Research
Orlando, Florida, United States
Berma Research Group
Plantation, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
Roskamp Institute
Tampa, Florida, United States
Four Rivers Clinical Research
Paducah, Kentucky, United States
J. Gary Booker, MD, APMC
Shreveport, Louisiana, United States
Maine Neurology
Scarborough, Maine, United States
The ICPS Group
Norwood, Massachusetts, United States
Alzheimer's Research Corporation
Paterson, New Jersey, United States
Global Medical Institutes
Princeton, New Jersey, United States
Social Psychiatry Research Institute
Brooklyn, New York, United States
The Mount Sinai Medical Center
New York, New York, United States
Behavioral Medical Research of Staten Island
Staten Island, New York, United States
The Neurological Institute, P.A.
Charlotte, North Carolina, United States
MedArk
Morgantown, North Carolina, United States
Neurology and Neuroscience Center of Ohio
Toledo, Ohio, United States
Tulsa Clinical Research, LLC
Tulsa, Oklahoma, United States
Rhode Island Mood and Memory Research Institute
East Providence, Rhode Island, United States
Todd Swick, MD, PA
Houston, Texas, United States
The Memory Clinic
Bennington, Vermont, United States
The Glennan Center for Geriatrics & Gerontology, Eastern Virginia Medical School
Norfolk, Virginia, United States
The Center for Excellence in Aging and Geriatric Health
Williamsburg, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol 03140-203
Identifier Type: -
Identifier Source: org_study_id